RTDS Group is very proud to join the battle against Coronavirus! As Coordinator of one of the 18 emergency H2020 projects funded by the European Commission in March this year, the SOLNATIDE project successfully started on April 1st 2020.
The goal of this project is to combat severe effects of Acute Respiratory Distress Syndrome (ARDS) as can be triggered by the Coronavirus through medication of a newly developed drug with therapeutic peptide compounds, so called Solnatide IMP.
The SOLNATIDE consortium and RTDS’ role
After preparing the Grant and Consortium Agreements in record time due to the urgent situation caused by the Corona pandemic, we now have kicked-off the SOLNATIDE project. As Coordinator, RTDS is responsible for the overall project coordination (Stephen Webb) as well as project management and communication (Natascha Miljković).
The Scientific Coordinator and initiator of the project Prof. Dr. Bernhard Fischer is CEO of the Viennese biotechnology company APEPTICO Forschung und Entwicklung GmbH which is proprietary owner of the medicinal product Solnatide IMP.
The H2020 funded project SOLNATIDE funds a clinical trial using Solnatide IMP for treating ARDS- and COVID-19 patients at the Munich University Hospital and other clinical sites treating COVID-19 patients.
Further information on SOLNATIDE
Currently, we are preparing information to be shared on a joint website representing all 18 EU Emergency Projects (to be established soon). Stay tuned for updates with the following information sources:
SOLNATIDE project LinkedIn showcase page
SOLNATIDE on Twitter
Download the SOLNATIDE Factsheet!